NanoViricides Inc 2026年季度报告

FORM10-Q QUARTERLY REPORT UNDER SECTION1320 OR 15(d)OFTHE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2026 Commission File Number:001-36081 NANOVIRICIDES,INC.(Exact name of Company as specified in its charter) 76-0674577 (IRS Employer Identification No.) 1 Controls DriveShelton, Connecticut 06484(Address of principal executive offices and zip code)(203) 937-6137(Company’s telephone number, including area code) Indicate by check mark whether the Company (1)has filed all reports required to be filed by Section13 or 15(d)of the ExchangeAct during the preceding 12months (or for such shorter period that the Company was required to file such reports), and (2)hasbeen subject to such filing requirements for the past 90days. Yes☒No☐ Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to besubmittedpursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorterperiod that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Company is a larger accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the Company is a shell company (as defined in Rule12b-2 of the Exchange Act). Securities registered pursuant to Section 12(b) of the Act: As of May 14, 2026 there were approximately 21,647,000 shares of common stock of the registrant issued and outstanding. NanoViricides,Inc.FORM10-QINDEXPART I FINANCIAL INFORMATION3Item 1. Financial Statements3Condensed Balance Sheets at March 31, 2026 (Unaudited) and June 30, 20253Condensed Statements of Operations for the Three and Nine Months Ended March 31, 2026 and 2025(Unaudited)4Condensed Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended March 31,2026 and 2025 (Unaudited)5Condensed Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (Unaudited)7Notes to the Condensed Financial Statements (Unaudited)8Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3. Quantitative and Qualitative Disclosures About Market Risk52Item 4. Controls and Procedures52PART II OTHER INFORMATION53Item 1. Legal Proceedings53Item 2. Unregistered Sales of Equity Securities and Use of Proceeds53Item 3. Defaults Upon Senior Securities53Item 4. Mine Safety Disclosures53Item 5. Other Information54Item 6. Exhibits and Reports on Form 8-K55Signatures56Certifications PART I. FINANCIAL INFORMATION NanoViricides,Inc.Condensed Statements of Operations(Unaudited) NanoViricides,Inc.Condensed Statements of Changes in Stockholders’ EquityFor the Nine months ended March 31, 2026(Unaudited) NanoViricides,Inc.Condensed Statements of Cash Flows(Unaudited) NANOVIRICIDES,INC.March 31, 2026NOTESTO THE CONDENSED FINANCIAL STATEMENTS(Unaudited) Note1– Organization and Nature of Business NanoViricides,Inc.(the“Company”)is a clinical stage nano-biopharmaceutical company specializing in thediscovery, development, and commercialization of drugs to combat viral infections using its unique and novelnanomedicines technology platform. The Company’s platform is based on host-mimicry, and thereby has uniquelyenabled development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmetneed in antiviral therapeutics. NanoViricides possesses its own facility that supports research and development anddrug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliantmanufacturing and packaging of drug products for human clinical trials, and early commercialization. The Companyhas several drugs in various stages of development. NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in theState of Connecticut. The Company’s fiscal year begins on July 1st and ends on the next June 30th of the calendaryear. The Company operates in one reportable business segment. Note2– Liquidity and Going Concern The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern,which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course ofbusiness. As reflected in the condensed financial statements, the Company has an accumulated deficit at March 31,2026 of approximately $154.8 million and a net loss of approximately $6.0 milli